Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P).
Hölscher T, Baumann M, Kotzerke J, Zöphel K, Paulsen F, Müller AC, Zips D, Thomas C, Wirth M, Troost EGC, Krause M, Löck S, Lohaus F. Hölscher T, et al. Among authors: kotzerke j. Cancers (Basel). 2022 Apr 21;14(9):2073. doi: 10.3390/cancers14092073. Cancers (Basel). 2022. PMID: 35565207 Free PMC article.
Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours.
Jentsch C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Krause M, Zips D, Troost EGC, Löck S, Kotzerke J, Steinbach J, Thames H, Baumann M, Beuthien-Baumann B. Jentsch C, et al. Among authors: kotzerke j. Radiother Oncol. 2016 Dec;121(3):447-452. doi: 10.1016/j.radonc.2016.07.024. Epub 2016 Aug 17. Radiother Oncol. 2016. PMID: 27544820
Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy.
Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M. Zschaeck S, et al. Among authors: kotzerke j. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1813-1822. doi: 10.1007/s00259-017-3742-0. Epub 2017 Jun 9. Eur J Nucl Med Mol Imaging. 2017. PMID: 28600646
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M. Löck S, et al. Among authors: kotzerke j. Radiother Oncol. 2017 Sep;124(3):533-540. doi: 10.1016/j.radonc.2017.08.010. Epub 2017 Aug 23. Radiother Oncol. 2017. PMID: 28843726
Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy.
Raschke F, Seidlitz A, Wesemann T, Löck S, Jentsch C, Platzek I, Petr J, van den Hoff J, Kotzerke J, Beuthien-Baumann B, Baumann M, Linn J, Krause M, Troost EGC. Raschke F, et al. Among authors: kotzerke j. Radiother Oncol. 2020 Sep;150:262-267. doi: 10.1016/j.radonc.2020.07.044. Epub 2020 Jul 31. Radiother Oncol. 2020. PMID: 32739316
381 results